Abstract Our purpose was to characterize changes in bone remodeling associated with localized radiation that models therapeutic cancer treatment in ovary-intact (I) and ovariectomized (OVX) mice and to evaluate the influence of radiation on the pattern of bone mineral remodeling. Young adult, female BALB/c mice, I and OVX, were used (n = 71). All mice were intravenously injected with 15 lCi 45 Ca. Thirty days post-45 Ca administration, the hind limbs of 17 mice were exposed to a single dose of 16 Gy radiation (R). The time course of 45 Ca excretion, serum CTx and osteocalcin markers, and cancellous bone volume fraction (BV/TV) and cortical thickness (Ct.Th) of the distal femur were assayed. Cellular activity and dynamic histomorphometry were performed. Irradiation resulted in rapid increases in fecal 45 Ca excretion compared to control groups, indicating increased bone remodeling. CTx increased rapidly after irradiation, followed by an increase in osteocalcin concentration. BV/TV decreased in the I mice following irradiation. Ct.Th increased in the OVX groups following irradiation. I?R mice exhibited diminished osteoblast surface, osteoclast number, and mineral apposition. Our murine model showed the systemic effects (via 45 Ca excretion) and local effects (via bone microarchitecture and surface activity) of clinically relevant, therapeutic radiation exposure. The I and OVX murine models have similar 
Introduction
Cancer survivors are a distinct population who may experience accelerated bone loss [1] over that of age-related osteoporosis. Women who undergo cancer therapy experience a 10-20 % increased fracture risk from treatmentinduced bone loss compared to healthy women [2, 3] . While decreased bone mineral density is associated with increased risk of fracture, recent work has demonstrated that remodeling status may be as predictive [4] [5] [6] [7] [8] [9] . Significantly, Riggs and Melton [9] found that high bone turnover substantially contributes to vertebral fracture risk because of its disruptive effect on the microarchitecture of cancellous bone. Furthermore, a recent study showed that recovery from radiation-induced skeletal damage following antiresorptive therapy may depend on ovarian function (i.e., pre-and postmenopausal status) [10] . Thus, insight into the extent and nature of posttreatment skeletal damage is also essential to determine the optimal preventive treatment management.
Some of the factors that adversely influence bone mineral remodeling in female cancer patients are inherent to current cancer treatment regimens. Premenopausal patients with pelvic-area cancers routinely undergo ovariectomy (OVX) to induce acute estrogen deficiency, to improve the treatment success of estrogen-sensitive cancers. These patients are at increased risk of osteoporosis. Patients are also at increased risk of bone fractures due to the adverse effects of the treatment itself (radiation and/or chemotherapy) [3, 11] . Thus, skeletal homeostasis of many patients with pelvic-area cancers is impacted by both acute estrogen deficiency and therapeutic doses of radiation.
Biochemical markers of bone turnover correlate to bone formation and resorption events and are measurable in blood or urine [4, 5] . They respond rapidly to treatments or other perturbations of bone turnover and can be assessed repeatedly in human subjects to track changes over time. However, a lack of specificity and high variability limit their utility in the clinical setting. Furthermore, while markers reflect changes in bone, they do not allow quantification of absolute changes expressed in bone units; only relative changes in the formation or resorption via collagen degradation are reported.
With bone being composed of *70 % mineral [12] and calcium representing nearly half of all bone mineral, calcium tracers offer a logical, noninvasive approach to measuring changes in bone turnover. Additionally, the ability to develop a kinetic model will assist insight into the in-and outflow of bone calcium during skeletal homeostasis and following systemic perturbations such as endocrine disruption and irradiation e.g., [13, 14] . Kinetic modeling will aid in understanding the nature of calcium flow rates (rapid, slow, or mixed), thus potentially addressing possible mechanisms for alterations in skeletal physiology affected by radiation. Implementation of a calcium tracer may allow early as well as longitudinal monitoring of bone responses to clinical therapies. Monitoring remodeling over time may be of value because alterations in bone remodeling precede changes in bone mineral density [15] [16] [17] .
Assaying the excretion of a calcium isotope (such as 41 Ca or 45 Ca) over time may provide a useful tool to noninvasively monitor changes in bone turnover. The utility of this approach has recently been demonstrated by quantifying bone turnover in response to bisphosphonate treatment [18] . The skeletal uptake of a calcium isotope (e.g., 41 Ca, which can be delivered in approximate nanocurie quantities) is compared with elution via excreta, quantified by accelerator mass spectrometry for 41 Ca, or using commonly available liquid scintillation counting systems for 45 Ca [18, 19] . These radioisotopes of calcium behave identically to dietary calcium in vivo; both 41 Ca and 45 Ca are already established as tracers used for calcium metabolism studies [20] . 45 Ca is a preferred marker in nonhuman animal models because of its short half-life (164 days), ease of measurement, and minimal expense. By quantifying the pharmacokinetics of this isotope in an animal subjected to irradiation and/or acute estrogen deficiency, this investigation aims to provide a basis for the clinical use of 41 Ca to noninvasively monitor bone turnover in humans. 45 Ca has been shown to be useful as a marker reflecting bone turnover, as validated by the Weaver group in a nonirradiated OVX rat [13] . The currently discussed work examines the effect of localized radiation on intact and OVX rodent models.
Overall, our purpose was to (1) validate a murine model to characterize the varying degrees of bone loss associated with therapeutic cancer treatments used to treat postmenopausal women (i.e., clinically relevant radiation dose in animals with acute estrogen deficiency)-a targeted and biologically equivalent dose of radiation to the appendicular skeleton was used in this investigation as a model of radiation therapy, for example, for treating endometrial cancer-and (2) evaluate the influence of clinically relevant, therapeutic radiation on patterns of bone remodeling in ovary-intact (I) and ovariectomized (OVX) murine models, correlating changes in bone surface activity and microarchitecture with bone mineral turnover as measured via 45 Ca excretion.
Methods
Five groups of skeletally mature BALB/c female mice (16 weeks old) were used for this study. The schematic representation of the design of this study is shown in Fig. 1 . Both I and OVX mice were chosen to mimic the clinical management of premenopausal and menopausal cancer patients undergoing radiation therapy (R), with appropriate controls. The examined groups were
, and (5) ''OVX?R'' (irradiated, n = 8). The number of mice within the BD, I-R, and I?R groups allowed for the killing of mice at multiple time points. Animals were also added to the I?R and OVX?R groups to account for possible loss of mice due to complications associated with radiation exposure (e.g., weight loss, organ toxicity). Mice were ovariectomized by the vendor 57 days prior to irradiation (Jackson Laboratory, Bar Harbor, ME). This study was approved by the University of Minnesota Institutional Animal Care and Use Committee.
Animal Husbandry
In order to monitor health, mice were weighed prior to irradiation and every day following irradiation for 10 days, as well as prior to placement in metabolic collection cages. Mice were housed three to five per cage, in a temperatureand humidity-controlled room, with free access to a standard rodent diet containing 18.6 % protein, 1 % calcium, and 1.5 IU/g added vitamin D (2018; Harlan Teklad, Madison, WI) and water. Mice were acclimated to a 12-h light/dark cycle. A minimal decline in mean body weight (0.5-1 g) in the radiation group compared to the nonirradiated group was observed, as expected. This small difference in body weight (2-4 %) is not expected to affect the results of our study. 45 Ca Delivery
After 1 week of acclimation in the vivarium, all mice were given an intravenous injection of 0.1 mL biostatic saline containing 15 lCi of 45 CaCl 2 . For the OVX?R and OVX-R groups, this injection was 27 days post-OVX (i.e., at skeletal homeostasis).
Estimation of Clinically Relevant Radiation Dose
Because a variety of fractionation schema have been used among clinical trials, Fowler [21] suggested using the normalized total dose (NTD), which is the biological effective dose (BED) normalized to a 2-Gy fraction.
d is the dose per fraction and a/b is the ratio of intrinsic radiosensitivity to repair the capability of a specified tissue [21] . The a/b ratio is assumed to be 3 [22, 23] . To facilitate radiation delivery, all mice in the I?R and OVX?R groups were anesthetized using a 0.05-mL intraperitoneal injection of a cocktail of ketamine (100 mg/kg) and xylazine (10 mg/ kg). All mice in the I-R and OVX-R groups were also anesthetized to control for the possible impact of anesthesia on bone metabolism. Once anesthetized, I?R and OVX?R mice were placed on a warmed acrylic plate for radiation delivery. Mice were secured to the plate using tape, to minimize possible movement during irradiation. A specially designed lead shield was placed over the body cranial to the femur, over the pelvis and caudal vertebrae, targeting the radiation exposure to only the hind limbs (Fig. 2a) . The shield over the main body had an average minimum thickness of 4 mm. Proper placement of the shield was confirmed using Kodak (Rochester, NY) EDR-2 film placed beneath the acrylic plate and approximately 60-cGy radiation exposure. Following shield placement verification, mice were monitored during the entire irradiation to ensure that they remained still with the critical organs properly protected. A source-to-surface of the leg distance of 30.4 cm was used. The total dose delivered, including that blocked by the shield, was 16 Gy. The total dose was verified using microthermoluminescent dosimeters. 45 
Ca Assay
While histomorphometric parameters are a cumulative measurement of changes over time, the kinetics of skeletal mineral remodeling can be measured by changes in excretion of 45 Ca. Details of 45 Ca measurement in excreta (e.g., feces and urine) by liquid scintillation were recently published by Hui et al. [24] . Briefly, feces and urine were collected for 24 h in metabolic cages approximately every 3 days for up to 60 days following 45 Ca administration. Feces were oven-dried at 80°C for 24 h, homogenized through grinding, then weighed. Results were standardized using 0.2 g feces from each dried sample for digestion into solution for liquid scintillation counting. This solution was attained by dissolving the feces fraction into 2 mL of concentrated (37 %) nitric acid. Twenty-four hours later, 1 mL of hydrogen peroxide was added to decolorize the solution. Another 24 h later, 0.4 mL of 3 M HCl and 0.8 mL of deionized water were added to the solution. After a third and final 24-h period in the digestion process, a 0.5-mL aliquot of the feces solution was combined with 15 mL of Ecolite scintillation cocktail (MP Biomedicals, Solon, OH) for 45 Ca isotope counting. Urine was collected directly from the cage bottom using 18 mL warm deionized water to rehydrate dried urine into solution. Results were standardized by concentrating 10 mL of the collected urine solution for liquid scintillation counting. The measured urine was concentrated by maintaining the sample at 80°C until completely dehydrated (24-48 h), then rehydrating it using 1 mL of warm deionized water. Once concentrated, 15 mL of Ecolite scintillation cocktail was immediately added to the urine sample for counting. 45 Ca radioactivity in the excreta was measured in disintegrations per minute (DPM) during a 6-minute count by liquid scintillation (LS 6500; Beckman Coulter, Indianapolis, IN). Variances in DPM due to the radioactive decay of the calcium isotope over time were accounted for by decay, correcting all results to the day of injection.
To examine the biodistribution of 45 Ca, five mice from the BD group were killed by CO 2 anoxia on days 1, 3, 5, and 16 after 45 Ca administration. After death, blood was immediately collected by cardiac puncture. Serum was obtained by centrifugation (5 min, 3,000 rpm). Femur, tibia, lumbar vertebrae, liver, kidneys, gut tissue (duodenum to anus, with contents), and quadriceps femoris muscle were removed; washed with isotonic saline solution; and weighed. Tissue samples were ashed for 48 h in a muffle furnace at 525°C, then dissolved into a solution of 1 mL of 3 M HCl and 1 mL of deionized water. A 0.5-mL aliquot of the digested organ sample was combined with 15 mL of Ecolite scintillation cocktail.
Time Course
In order to examine the time course of the radiation effect on bone remodeling, mice from the I?R and I-R groups were killed by CO 2 anoxia at different time points after irradiation. Five mice from both the I-R and I?R groups were killed on days 3 and 8 postradiation, with the remaining I-R (n = 7) and I?R (n = 9) mice being killed 30 days postradiation. The OVX?R and OVX-R groups were killed only at 30 days after irradiation.
C-Terminal Telopeptide and Osteocalcin Assay
After death, blood was immediately collected by cardiac puncture in order to measure C-terminal telopeptide (CTx), a metabolic product of type 1 collagen destruction (i.e., a marker of bone resorption) and osteocalcin (i.e., a peptide associated with bone mineralization). These measurements were necessary to validate radioisotope-associated bone responses with established biochemical markers. Both of these systemic features were assayed by sandwich ELISA kits (Biomedical Technologies, Stoughton, MA). The CTx kit had a sensitivity of 1 ng/mL, intra-assay variation of 6 % (95 % limits), and interassay variation of 8 % (95 % limits). The osteocalcin kit had a range of 1-50 ng/mL, a Fig. 2 a Shielding designed to deliver radiation to the hind limbs while protecting the rest of the animal. A specially designed lead shield (4 mm thickness) was placed over the body cranial to the femur, over the pelvis and caudal vertebrae, targeting the radiation exposure to only the hind limbs. Proper placement of shielding was confirmed using Kodak EDR-2 film placed beneath the animal and an acrylic plate. Total dose delivered, including the shielding placement exposure, was 16 Gy. Total dose in the radiation field and under the block was verified using thermoluminescent dosimeters. b Hematoxylin and eosin (H&E) stain (distal femur). I Demineralized distal femora vacuum-embedded in paraffin were sectioned (5 lm) and stained with H&E, then imaged at 9100. II Number of osteoclasts (Oc.N). III Surface occupied by functional osteoblasts (Ob.S). c Dynamic labeling (proximal tibia). Twelve and 29 days postradiation, all mice (n = 12) received tetracycline and calcein intravenous injections, respectively. Mice were killed 5 days later (34 days postradiation). Fixed, undemineralized tibiae were vacuum-embedded in methyl methacrylate, sectioned at 5 lm on an EXAKT system, and imaged under UV light with a 940 objective on a Zeiss AxioPlan II. Images were captured and stitched together by Image-Pro v7.0 using a Stage-Pro module (Media Cybernetics). A representative figure of collated images of a complete tibia with dual labeling is shown in c (I). A small region of tibia with dual labeling is shown for control mice (II) and for irradiated mice (III) sensitivity of 0.4 ng/mL, intra-assay variation of 4 %, and interassay variation of 6 %.
OVX Verification
Wet uterine weights of mice from the I?R, I-R, OVX?R, and OVX-R groups were measured immediately postmortem to verify the efficacy of vendor-performed ovariectomies. Ovary-intact mouse uteri weighed an average of 0.0614 ± 0.0052 g SEM, while the average for OVX mice was 0.0137 ± 0.0020 g SEM. This reduction in uterine weight of nearly 80 % (p \ 0.001) confirms the complete excision of all ovarian tissue.
MicroCT and Histological Analyses
Bone microarchitecture of I?R, I-R, OVX?R, and OVX-R mice was analyzed with a microCT scanner (lCT 35, Cone-Beam microCT; Scanco Medical, Bassersdorf, Switzerland) using protocols described by Bouxsein et al. [25] . Immediately after death, femora (n = 20) were placed in 70 % ethanol. The distal femoral metaphysis was scanned within a region of 0.3-1.0 mm from the growth plate in order to avoid the primary spongiosa, with a slice thickness of 7-lm resolution (100 slices) at 70 kVp. Using the manufacturer's software, relative cancellous bone volume fraction (BV/TV, %; i.e., the ratio of the segmented bone volume to the total volume of the region of interest) and cortical thickness (Ct.Th, mm) were estimated. Specimens were then demineralized with 0.5 M EDTA, embedded in paraffin following dehydration, sectioned at 5 lm, and stained with hematoxylin and eosin. Sections were imaged at 9100, and bone surface cellular activity was quantified as percent total trabecular perimeter (Tb.P), surface occupied by osteoblasts (Ob.S), and number of osteoclasts (Oc.N) (Fig. 2b) .
Dynamic Histomorphometry
In order to evaluate bone activity over time, some mice were serially injected with fluorochromes to label active surfaces [26, 27] . Twelve mice (same sex and age as previous) were irradiated in the hind limb with 16 Gy as described earlier.
Twelve days later, all mice received 37.5 mg/kg tetracycline i.v. This acts to systemically mark actively forming bone surfaces. Seventeen days later (29 days postradiation), all mice received 37.5 mg/kg i.v. calcein. Mice were killed 5 days later (34 days postradiation), thereby allowing for full incorporation of the fluorochrome. Tibiae were dissected out, soft tissues were removed, and bone was fixed in 10 % buffered formalin for 24 h. Specimens were then transferred to cold 70 % ethanol until they were vacuum-embedded in methylmethacrylate. These blocks were sectioned at 5 lm in the coronal plane and processed by the EXAKT system (EXAKT Technologies, Oklahoma City, OK). Bone sections were imaged under UV light (D350/50 excitation, D460/50 emission) on an AxioPlan II (Zeiss, Oberkochen, Germany) equipped with an OASIS Glide S2 motorized XY stage from Objective Imaging (Cambridge, UK). Sections were captured with a 940 objective and stitched into a single high-resolution image by Image-Pro v7.0 with the Stage-Pro module (Media Cybernetics, Rockville, MD) as shown in Fig. 2c . Distances between fluorochrome labels and label lengths were measured with ImageJ software (rsb.info.nih.gov/ij).
Statistical Analysis 45 Ca excretion results were analyzed using a linear mixed model in SAS, version 9.2 (SAS Institute, Cary, NC) due to the presence of repeated measures. For comparisons of radiation versus nonradiation mice within specific group cohorts (I?R, I-R, OVX?R, and OVX-R), we fit main effects for radiation and day as well as an interaction term. For comparisons of mice with matching radiation treatments between group cohorts, a similar model was used but with group cohort as an effect instead of radiation. We calculated differences with relation to the outcome of 45 Ca as well as differences in rate of change (slope) of 45 Ca excretion over time.
CTx and osteocalcin were compared between radiation and nonradiation mice within each group cohort by the use of two-sample t-tests.
Histomorphometric data were compared between radiation and nonradiation mice within each group cohort by two-sample t-tests. Comparisons were also made between specific group cohorts for both radiated and nonradiated mice. For the I?R and I-R groups, a generalized linear model was utilized due to the presence of three time points. Both histomorphometric outcomes were compared between each pair of time points after using a Tukey-Kramer adjustment for multiple comparisons. A correlation between cumulative 45 Ca and BV/TV for the I?R group was also calculated using the Pearson correlation coefficient.
Lastly, we compared mice with the same radiation treatment in the I?R and I-R groups between days 3, 8, and 30 for cumulative 45 Ca excretion and BV/TV using a one-way analysis of variance (ANOVA). Ca injection (Fig. 3c) . 45 
Results

Biodistribution and Pharmacokinetics of
Ca Excretion
The impact of radiation on bone mineral remodeling as measured by 45 Ca excretion was readily evident in all irradiated mice, with increased excretion indicating higher bone turnover (Table 1 ; Fig. 4) . Notably, the onset of radiation effects was rapid in all irradiated mice, showing an increase of 45 Ca excretion by day 4 postradiation compared to the nonirradiated mice (Fig. 4 ). Significant differences in 45 Ca were found between radiation and nonradiation mice within the I?R and I-R groups only (estimate = -889.13, p \ 0.001), with the increased 45 Ca excretion indicating an increase in bone turnover in the I?R group compared to the I-R group. There were no significant differences in the rate of change over time within the four group cohorts of interest. Complete results are shown in Table 2 .
CTx and Osteocalcin Assay
To compare the results of 45 Ca as a bone mineral turnover marker with established bone biochemical markers, we measured serum concentrations of systemic markers of bone resorption (CTx) and formation (osteocalcin).
Significant differences in CTx measures were found among the ovary-intact group, with higher levels being observed in I?R mice compared to I-R mice on day 3 A C B Microstructural Analysis Using MicroCT Figure 5 illustrates the resultant changes in bone microarchitecture of both the I and OVX distal femora following irradiation. The I?R group experienced a time-dependent decrease in trabecular BV/TV that was sizeable and significant by day 30 after irradiation (Fig. 5) . Comparing group I-R versus OVX-R, there was a significant difference for Ct.Th (estimate = 0.0244, p = 0.047) but not BV/TV. Irradiation had no significant effect on histomorphometric parameters examined in OVX mice, though there was a slight increase in Ct.Th at 30 days.
Using a one-way ANOVA, we compared mice with the same radiation treatment in the I?R and I-R groups between days 3, 8, and 30 for both outcomes. We found significant differences between time points for radiated mice only with BV/TV as the outcome after multiple comparison adjustments were performed. There was a significant difference between the I?R day 3 cohort compared to the I-R day 30 cohort (estimate = 0.0534, p \ 0.001) and between the I?R day 8 cohort compared to the I-R day 30 cohort (estimate = 0.0403, p = 0.002). There was no significant difference between days 3 and 8.
When comparing cumulative 45 Ca versus BV/TV for the I?R group, the Pearson correlation coefficient was highly significant (estimate = -0.998, p \ 0.001) (Fig. 6 ).
Histology/Surface Cellular Activity
Surface activity parameters of static histomorphometric and dynamic histomorphometric parameters are shown in Table 3 . In I mice, both osteoclasts and osteoblasts seemed to be affected by the local radiation, with a resultant decrease in trabecular perimeter by 30 days. Statistical significance was not observed, perhaps due to the small number of subjects and the large variability in the I?R group. As expected, OVX appeared to result in a lower percent of bone perimeter covered by functional osteoblasts and osteoclasts. Delivery 45 Ca excretion in intact mice were apparent during the first week after treatment, emerging transiently (i.e., approximately for 2 weeks). There appeared to be a smaller effect of radiation on mice ovariectomized 57 days prior Compared to control, label 1 showed 36.8 % reduction in length, with 88.7 % reduction in label 2 17 days later. This represents 51.8 % reduction in the rate of change in label length due to radiation during the experimental period (12-29 days postradiation). Compared to control, radiation-treated mice experienced a modest reduction in mineral apposition rate (MAR, 1.78 lm/day or 16 %/day). A 35 % (3,443 DPM/0.2 g feces) increase in excretion of 45 Ca was observed in the same time period, with a majority of the excretion observed at 12-20 days postradiation (Fig. 4) ; the day 12 increase was 45 %, while there was only a 5.7 % increase at day 29.
Discussion and Conclusions
Although therapeutic radiation and OVX are necessary components for the effective treatment of rectal, endometrial, and cervical cancers, the resultant radiation dose and acute estrogen deficiency contribute to an increased fracture risk and a decreased quality of life [7] . Although comorbidities have both been shown to affect bone health, little information is available on the dynamics of bone remodeling in response to these influences. This study was designed to gain insight into the longitudinal response of bone mineral remodeling due to cancer therapy in pre-and postmenopausal patients undergoing radiation treatment.
Radiation Effect on Bone Remodeling in I versus OVX Mice
The purpose of this study was to evaluate the impact of radiation on bone in both ovary-intact mice and mice after acute estrogen deficiency induced by OVX. However, to accomplish this task, the influence of OVX itself on the methods used in this study had to be evaluated to adequately identify changes in the pattern of bone remodeling specific to radiation exposure. The known acute effect of estrogen deficiency to increase bone turnover [28] appears to have been reflected in the significant decrease in cortical thickness in OVX-R mice compared to I-R mice at 87 days post-OVX (day 30, Fig. 4) . Note that the analogous decrease in i.e., the ratio of the segmented bone volume to the total volume of the region of interest) and cortical thickness (Ct.Th, mm). Data are presented as group mean ± SEM, n = 5-7 per group. Significant differences were observed in the I ± R group for BV/TV at day 8 (p = 0.051) and day 30 (p = 0.016) but not in the OVX ± R group at day 30. A significant difference in Ct.Th was observed in the I ± R group at day 8 (p = 0.001) and the OVX ± R group at day 30 (p \ 0.001). Time-dependent changes in BV/TV were significant (adjusting for multiple comparisons) between the I ± R day 3 cohort compared to the I ± R day 30 group (p \ 0.001) and between the day 8 compared to the day 30 set (p = 0.002). There was no significant difference between days 3 and 8. Radiation-induced reductions in BV/TV were greater in intact mice compared to OVX mice, as shown by the excreta data (Fig. 4) BV/TV due to OVX only (OVX-R vs. I-R) was not statistically significant. Interestingly, the effects of radiation varied depending on whether the ovaries were intact or removed, with the main difference manifested as changes in bone microarchitecture occurring within the cancellous or cortical bone. Radiation-induced changes in the I groups were primarily within the cancellous bone, while in OVX animals they were observed mainly within the cortices. Cortical thickness decreased as a result of OVX but increased as an effect of radiation in the OVX?R group compared to the OVX-R group. That is, the significant decrease in cortical thickness, caused by acute estrogen deficiency, was nearly reversed by remodeling in OVX?R mice induced after radiation exposure. A radiation-induced increase in the cortical thickness of OVX BALB/c mice is consistent with the findings of Klinck et al. [29] , though the radiation exposure examined by this group was a small fraction of the 16 Gy employed by the present study (i.e., microCT scans).
Examining the time course of the radiation effect (i.e., increased bone remodeling) in ovary-intact mice revealed an early increase in 45 Ca excretion. This is a manifestation of the resultant bone remodeling as evidenced in systemic osteoclastic activity (measured by serum CTx) and osteoblast activity (measured by serum osteocalcin). The time course kinetics of mineral turnover measured by 45 Ca excretion is further confirmed with dynamic histomorphometry. As expected, the reduction in mineralization (as measured using MAR and label length) was associated with increased 45 Ca excretion. However, the change in MAR reflects accumulated change over the time period postradiation (12-29 days), limiting observation of the real temporal change in bone matrix maturation. Although 45 Ca seems to show rapid change in mineral turnover, it represents whole-body turnover, whereas MAR represents local effects of targeted radiation, complementing what is observed in the 45 Ca assay. An early increase in bone resorption is consistent with the findings of Willey et al. [30] . However, their study focused on low-dose (2 Gy) whole-body radiation, resulting in significant differences compared with local radiation since unexposed skeletal elements may support recovery in the damaged regions. Additionally, our study indicates that this loss may be due to changes in osteoclastic and osteoblastic activities, rather than osteoclast activity alone. This is further supported by the phenomenon observed at the cellular level with decreased osteoclast number, osteoblast surface, and trabecular parameters at day 30. Though irradiation of ovary-intact animals showed large changes in the number of functional osteoclasts and osteoblastic population, it appeared to have a much smaller effect on OVX mice.
The early increases in bone turnover markers were followed by significant decreases in BV/TV of the cancellous bone, as measured by microCT-based histomorphometric analysis. As expected, OVX alone appeared to result in a lower percent of bone perimeter covered by functional osteoblasts and osteoclasts. However, delivery of 16 Gy did not appear to significantly impact bone. Lack of a significant increase in either 45 Ca excretion or markers of bone turnover after radiation in OVX mice may suggest that either (1) the changes in bone turnover occurred earlier in OVX mice before markers of bone turnover or calcium excretion were measured as radiation was delivered 57 days post-OVX (Fig. 1) or (2) the decrease in cortical bone occurred independently of 45 Ca labeling, which suggests that 45 Ca may preferentially label cancellous bone, possibly due to a higher turnover and larger active bone surface compared to cortical bone. At the cellular level, changes in Ob.S and Oc.N were minimal, with slight increases in Oc.N. A very small reduction in BV/TV was observed (Fig. 5 ). This suggests option (1) as a possible explanation. A lower number of responding cells, possibly due to post-OVX cellular adaptation, may underlie the minimal effect of radiation on bone remodeling. In our study, delayed radiation treatment after OVX represents a model similar to the older patient who undergoes radiation treatment long after menopause. In the future, an experiment could be designed to assess OVX and radiation consecutively or within a short time difference to assess cumulative effects, modeling the patient who undergoes radiation treatment following menopause.
Biodistribution and Pharmacokinetics of 45 
Ca
The elevated concentration of 45 Ca in the gut tissue on day 1, rapidly dropping by day 5, is suggestive of the migration of endogenous 45 Ca to feces rather than urine. Spinal 45 Ca on day 1 being nearly equal to the concentration of 45 Ca in the gut tissue also indicates a rapid uptake of calcium into this part of the skeleton. The absence of 45 Ca in nonskeletal specimens relative to sustained levels of 45 Ca in skeletal specimens indicates that the only significant reservoir of 45 Ca at the time of irradiation (30 days post-45 Ca administration) was in the skeleton. Combined with the steady state of 45 Ca excretion attained by 30 days post-45 Ca administration, these findings indicate that changes in the concentration of 45 Ca in excreta after irradiation of the mice may therefore be a marker for the effects on bone remodeling caused by radiation exposure. Since the majority of excreted 45 Ca was via the feces, studies of the time course of 45 Ca pharmacodynamics will require that fecal excretion be the focus for long-term monitoring via the 45 Ca assay. Specifically, postradiation increases in 45 Ca excretion would directly reflect increased bone mineral resorption, as confirmed by increased serum osteocalcin concentrations.
Correlation of Fecal 45 Ca and BV/TV
The significance of increased 45 Ca excretion in both mouse models (I and OVX) following radiation exposure establishes the benefit of using a biomineral marker for monitoring the impact of therapeutic radiation on bone remodeling. For example, radiation exposure caused a significant early increase in 45 Ca excretion, and the significant (p \ 0.040) correlation between cumulative 45 Ca excretion and decreasing BV/TV (Fig. 6) further verified the usefulness of a biomineral marker as a noninvasive, real-time means for predicting and assessing small changes in bone microarchitecture.
Strength and Limitations
The early increases of 45 Ca excretion, prior to measurable changes in BV/TV, support the use of a calcium tracer for identifying the appropriate time for early intervention to prevent or minimize bone loss. This investigation demonstrates that evaluation of mineral flux with 45 Ca in excreta provides a direct, real-time, noninvasive method to monitor treatment-induced changes in bone mineral remodeling that occur rapidly. Importantly, it verifies the efficacy of using a calcium tracer to monitor the early onset and rapid bone turnover associated with therapeutic radiation, thus establishing a clinically relevant murine model for radiation treatment of premenopausal cancer survivors. Nevertheless, there are some limitations. First, small sample sizes within each treatment group of mice may have limited the statistical significance of differences in 45 Ca excretion, primarily within the small differences observed in the OVX?R and OVX-R groups. Also, the variation in DPM values is relatively large. We expect that a larger sample size would tend to produce greater statistical significance for the daily differences observed within each group. Second, the experimental period was brief (2 months); a long-term study may be helpful in gaining insight into the inherent course of recovery. Finally, markers of bone turnover were not measured at baseline, prior to OVX. In the future, correlations of 45 Ca with bone microstructure and bone mineral content or bone mineral density at a range of time points will be important for developing a predictive model using an isotopic biomarker.
Translational Importance
We have recently reported, in a study employing quantitative computed tomography, that patients with ovarian or endometrial cancer experience an accelerated and distinct pattern of trabecular bone loss from systemic chemotherapy versus local pelvic radiation [31] . The murine models described here simulate the pelvic radiation dosage administered to pre-and postmenopausal women who have endometrial or rectal cancer. The selected experimental radiation dose is considered to be radiobiologically equivalent to the average prescribed clinical dose [21] .
Bone damage varies with the dose and the nature of radiation exposure (i.e., local or whole-body) [32] [33] [34] [35] . The murine models described here demonstrated that 45 Ca in an ovary-intact model is sensitive to small changes in skeletal turnover due to local radiation. It is therefore useful for early and long-term monitoring of systemic bone remodeling and able to show differences related to the etiology of the skeletal damage. Many cancer survivors experience age-related or treatment-related menopause. Hui et al. [10] recently observed that recovery from skeletal damage may depend on radiation dose with or without ovarian function (i.e., pre-and postmenopausal). The accurate determination of skeletal damage and ovarian status post-cancer treatment may also be essential to select an optimal antiresorptive pharmacotherapy. This study lays the groundwork to develop a diagnostic marker sensitive enough to design individualized protocols for patients who become osteopenic resulting from cancer treatments. Furthermore, microdose concentrations of 41 Ca are known to be highly sensitive to short-term and long-term bone remodeling [18, 19] ; since 45 Ca can act as a surrogate marker of 41 Ca [20] , we expect that 41 Ca can be used for analogous investigations in the clinical setting.
In summary, therapeutic radiation affects the pattern of bone mineral remodeling in different ways depending on the ovarian status of the recipient. Use of a real-time, noninvasive 45 Ca assay may be useful as a marker to monitor the time course of the bone remodeling response after therapeutic interventions (e.g., radiation exposure) for cancer treatments. Understanding the extent and nature of changes in remodeling and related skeletal damage will be beneficial to optimizing potential interventions during or following cancer therapy.
